Moving forward, perhaps no recent development in the use of RT in metastatic prostate cancer has captured greater attention than the use of radium-223 in metastatic castration-resistant prostate cancer (mCRPC).
Kristopher Dennis, MD, FRCPC
Advertisement
Articles by Kristopher Dennis, MD, FRCPC
Patients with advanced progressive cancer require care plans that address their physical, emotional, and psychosocial needs, as well as their goals of care.
Advertisement
Latest Updated Articles
- Palliative RT Research in Prostate Cancer: Understanding the Past, Anticipating the Future
Published: April 15th 2014 | Updated:
- Palliative Care and Oncology: Integration Leads to Better Care
Published: November 30th 2011 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Pembrolizumab Combo Significantly Improves PFS/OS in Recurrent PROC
2
Tarlatamab Plus Chemo/IO Regimens Are Safe, Elicit Responses in ES-SCLC
3
ASCENT-03 Trial Supports Standard Use of Sacituzumab Govitecan in mTNBC
4
TUB-040 Elicits Early Responses in Platinum-Resistant Ovarian Cancer
5
